CYP17A1 and breast carcinoma: Combination with drugs that target CDK4/6, CYP17A1, or the PI3K/AKT/mTOR pathway, immunotherapies, or conventional treatments such as chemotherapy and radiotherapy may enhance the efficacy of breast cancer treatment [50,51].